Rupitasertib

DB15431InvestigationalSmall molecule

M-2698 is under investigation in clinical trial NCT01971515 (First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies).

Mechanism: Pharmacologically active on RAC-gamma serine/threonine-protein kinase and RAC-alpha serine/threonine-protein kinase
Curator reviewed
Formula / weight: C₂₁H₁₉ClF₃N₅O · 449.86 g/mol (avg)
Also known as: M-2698 · MSC2363318A

Resolves to

Compound

Structure

InChIKeyHXAUJHZZPCBFPN-QGZVFWFLSA-NSMILESNC(=O)C1=CC=CC2=C1N=CN=C2N[C@H](CN1CCC1)C1=CC(=C(Cl)C=C1)C(F)(F)F

Targets

What you can answer from here — as of June 15, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Rupitasertib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.